


## Dihydrouracil

## Chemical Properties

CAS No. :	504-07-4
Formula:	C <sub>4</sub> H <sub>6</sub> N <sub>2</sub> O <sub>2</sub>
Molecular Weight:	114.1
Storage:	Powder: -20°C for 3 years   In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



## Biological Description

Description	5,6-Dihydrouracil (5,6-Dihydrouracil) is an intermediate breakdown product of uracil.
Targets(IC50)	Endogenous Metabolite

## Solubility Information

Solubility	DMSO: 3.33 mg/mL (29.18 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (8.76 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

## Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	8.7642 mL	43.8212 mL	87.6424 mL
5 mM	1.7528 mL	8.7642 mL	17.5285 mL
10 mM	0.8764 mL	4.3821 mL	8.7642 mL
50 mM	0.1753 mL	0.8764 mL	1.7528 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

- Sreekumar A, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. *Nature*. 2009 Feb 12;457(7231):910-4. doi: 10.1038/nature07762.
- Hofmann U, Schwab M, Seefried S, et al. Sensitive method for the quantification of urinary pyrimidine metabolites in healthy adults by gas chromatography-tandem mass spectrometry[J]. *Journal of Chromatography B*, 2003, 791(1-2):371-380.
- André B. P. van KUILENBURG, Stroomer A E M, Lenthe H V, et al. New insights in dihydropyrimidine dehydrogenase deficiency: a pivotal role for beta-aminoisobutyric acid? [J]. *Biochemical Journal*, 2004, 379(1):119-24.
- Grem J L. Intratumoral molecular or genetic markers as predictors of clinical outcome with chemotherapy in colorectal cancer [J]. *Seminars in Oncology*, 2005, 32(1):120-127.
- Assmann B, Hoffmann G F, Wagner L, et al. Dihydropyrimidinase deficiency and congenital microvillous atrophy: coincidence or genetic relation? [J]. *Journal of Inherited Metabolic Disease*, 1997, 20(5):681-8.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E\_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481